187 related articles for article (PubMed ID: 15771622)
21. High CHI3L1 expression is associated with glioma patient survival.
Steponaitis G; Skiriutė D; Kazlauskas A; Golubickaitė I; Stakaitis R; Tamašauskas A; Vaitkienė P
Diagn Pathol; 2016 Apr; 11():42. PubMed ID: 27121858
[TBL] [Abstract][Full Text] [Related]
22. Expression of the chitinase family glycoprotein YKL-40 in undifferentiated, differentiated and trans-differentiated mesenchymal stem cells.
Hoover DJ; Zhu V; Chen R; Briley K; Rameshwar P; Cohen S; Coffman FD
PLoS One; 2013; 8(5):e62491. PubMed ID: 23671604
[TBL] [Abstract][Full Text] [Related]
23. Anti-YKL-40 antibody and ionizing irradiation synergistically inhibit tumor vascularization and malignancy in glioblastoma.
Shao R; Francescone R; Ngernyuang N; Bentley B; Taylor SL; Moral L; Yan W
Carcinogenesis; 2014 Feb; 35(2):373-82. PubMed ID: 24282289
[TBL] [Abstract][Full Text] [Related]
24. YKL-40 tissue expression and plasma levels in patients with ovarian cancer.
Høgdall EV; Ringsholt M; Høgdall CK; Christensen IJ; Johansen JS; Kjaer SK; Blaakaer J; Ostenfeld-Møller L; Price PA; Christensen LH
BMC Cancer; 2009 Jan; 9():8. PubMed ID: 19134206
[TBL] [Abstract][Full Text] [Related]
25. Association between YKL-40 and adult primary astrocytoma.
Zhang W; Kawanishi M; Miyake K; Kagawa M; Kawai N; Murao K; Nishiyama A; Fei Z; Zhang X; Tamiya T
Cancer; 2010 Jun; 116(11):2688-97. PubMed ID: 20499402
[TBL] [Abstract][Full Text] [Related]
26. YKL-40 protein expression in the early developing human musculoskeletal system.
Johansen JS; Høyer PE; Larsen LA; Price PA; Møllgård K
J Histochem Cytochem; 2007 Dec; 55(12):1213-28. PubMed ID: 17712177
[TBL] [Abstract][Full Text] [Related]
27. Serum YKL-40 predicts adverse clinical outcomes in patients with chronic heart failure.
Bilim O; Takeishi Y; Kitahara T; Ishino M; Sasaki T; Suzuki S; Shishido T; Kubota I
J Card Fail; 2010 Nov; 16(11):873-9. PubMed ID: 21055651
[TBL] [Abstract][Full Text] [Related]
28. A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers.
Faibish M; Francescone R; Bentley B; Yan W; Shao R
Mol Cancer Ther; 2011 May; 10(5):742-51. PubMed ID: 21357475
[TBL] [Abstract][Full Text] [Related]
29. YKL-39 (chitinase 3-like protein 2), but not YKL-40 (chitinase 3-like protein 1), is up regulated in osteoarthritic chondrocytes.
Knorr T; Obermayr F; Bartnik E; Zien A; Aigner T
Ann Rheum Dis; 2003 Oct; 62(10):995-8. PubMed ID: 12972480
[TBL] [Abstract][Full Text] [Related]
30. Isolation and sequence of a novel human chondrocyte protein related to mammalian members of the chitinase protein family.
Hu B; Trinh K; Figueira WF; Price PA
J Biol Chem; 1996 Aug; 271(32):19415-20. PubMed ID: 8702629
[TBL] [Abstract][Full Text] [Related]
31. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes.
De Ceuninck F; Gaufillier S; Bonnaud A; Sabatini M; Lesur C; Pastoureau P
Biochem Biophys Res Commun; 2001 Jul; 285(4):926-31. PubMed ID: 11467840
[TBL] [Abstract][Full Text] [Related]
32. Role of chitinase-like proteins in cancer.
Kzhyshkowska J; Yin S; Liu T; Riabov V; Mitrofanova I
Biol Chem; 2016 Mar; 397(3):231-47. PubMed ID: 26733160
[TBL] [Abstract][Full Text] [Related]
33. Serum YKL-40, a new prognostic biomarker in cancer patients?
Johansen JS; Jensen BV; Roslind A; Nielsen D; Price PA
Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):194-202. PubMed ID: 16492905
[TBL] [Abstract][Full Text] [Related]
34. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.
Iwamoto FM; Hottinger AF; Karimi S; Riedel E; Dantis J; Jahdi M; Panageas KS; Lassman AB; Abrey LE; Fleisher M; DeAngelis LM; Holland EC; Hormigo A
Neuro Oncol; 2011 Nov; 13(11):1244-51. PubMed ID: 21831900
[TBL] [Abstract][Full Text] [Related]
35. YKL-40--a novel biomarker in clinical practice?
Kazakova MH; Sarafian VS
Folia Med (Plovdiv); 2009; 51(1):5-14. PubMed ID: 19437893
[TBL] [Abstract][Full Text] [Related]
36. Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia.
Kucur M; Isman FK; Balci C; Onal B; Hacibekiroglu M; Ozkan F; Ozkan A
Urol Oncol; 2008; 26(1):47-52. PubMed ID: 18190830
[TBL] [Abstract][Full Text] [Related]
37. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.
Hormigo A; Gu B; Karimi S; Riedel E; Panageas KS; Edgar MA; Tanwar MK; Rao JS; Fleisher M; DeAngelis LM; Holland EC
Clin Cancer Res; 2006 Oct; 12(19):5698-704. PubMed ID: 17020973
[TBL] [Abstract][Full Text] [Related]
38. YKL-40 protein expression is not a prognostic marker in patients with primary breast cancer.
Roslind A; Knoop AS; Jensen MB; Johansen JS; Nielsen DL; Price PA; Balslev E
Breast Cancer Res Treat; 2008 Nov; 112(2):275-85. PubMed ID: 18157633
[TBL] [Abstract][Full Text] [Related]
39. Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis.
Furuhashi K; Suda T; Nakamura Y; Inui N; Hashimoto D; Miwa S; Hayakawa H; Kusagaya H; Nakano Y; Nakamura H; Chida K
Respir Med; 2010 Aug; 104(8):1204-10. PubMed ID: 20347285
[TBL] [Abstract][Full Text] [Related]
40. High serum YKL-40 level in a cohort of octogenarians is associated with increased risk of all-cause mortality.
Johansen JS; Pedersen AN; Schroll M; Jørgensen T; Pedersen BK; Bruunsgaard H
Clin Exp Immunol; 2008 Feb; 151(2):260-6. PubMed ID: 18070151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
